Additionally, research indicates that factors such as high expression of CYFRA 21-1, IL-6, IL-17, and genes like SDHAF2, MRPS34, MRPL11, COX8A, and genetic mutations in TP53, KRAS, and CDKN2A are associated with poor prognosis in ICC (Boerner et al., 2021), suggesting new directions for adjuvant therapy. This evidence concerns the gene MRPL11 and intrahepatic cholangiocarcinoma.